Amarin Corp Plc (AMRN)

[ziploc_1]

To be substantially profitable, a generic drug must have substantial volume...An AG of Vascepa would have huge volume because it is safe and effective in very common and very severe CardioVascularDiseases and of moderate expense...It would be sold in the U.S. and in China and have large volume.

Amarin would have the upper hand over Generics as to volume and cost of API...Generic companies would be infringing and would need to be worrying about law suits...In two or three years, patented statin-Vascepa combo drugs would be available.

I believe that, after the negotiations on price with EU countries and with China are completed, an AG of Vascepa could be profitably marketed in the U.S.